Overall survival in patients with FIGO stage IVA cervical cancer

FIGO stage IVA cervical cancer is a unique diagnosis that conveys a poor prognosis. Despite the use of PET/CT for staging, concurrent chemotherapy, and image-guided brachytherapy, overall survival (OS) in these patients is low. Treatment requires aggressive use of radiotherapy and chemotherapy. We report results of a prospective observational cohort study for patients with de novo stage IVA cervical cancer treated at a single institution. Patients with a new diagnosis of stage IVA cervical cancer treated at an academic institution between 1997 and 2020 were prospectively monitored. Staging was retroactively assigned using the 2018 FIGO staging system. All patients had a PET/CT prior to treatment and were treated with definitive intent radiotherapy with or without chemotherapy. The primary outcome of interest was OS. Secondary outcomes were local control, progression-free survival (PFS), and disease-specific survival (DSS). 32 patients with de novo stage IVA cervical cancer were treated with definitive intent radiotherapy. Median follow-up time was 4.27 years (1.31–10.35). 22/32 (69%) of patients received brachytherapy as a part of their definitive treatment, and 28/32 (88%) received chemotherapy concurrently with radiotherapy. 14/32 (44%) of patients had no evidence of disease at last follow-up. The 5-year local control, PFS, DFS, and OS estimates were 79%, 49%, 53%, and 48%, respectively. On multivariate analysis, complete metabolic response was associated with a statistically significant improvement in PFS (HR = 0.256, 95% CI = 0.078–0.836, p = 0.024) and OS (HR = 0.273, 95% CI 0.081–0.919). These data demonstrate a robust OS in patients with stage IVA cervical cancer when treated with definitive chemoradiotherapy. •Stage IVA cervical cancer is a disease with a classically poor prognosis.•32 patients with stage IVA disease treated with definitive chemoradiotherapy were prospectively observed.•69% of patients received brachytherapy, and 88% of patients received concurrent chemotherapy.•Overall survival was 48% at five years and 44% of patients had no evidence of disease at last follow-up.•Complete metabolic response was associated with an improved progression-free and overall survival.